Related Experiment Video
Updated: Jun 19, 2026

Cortical Neurogenesis: Transitioning from Advances in the Laboratory to Cell-Based Therapies
Published on: July 19, 2007
How a US regulator can encourage new science
1Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA. douglas.throckmorton@fda.hhs.gov
Abstract:
The Center for Drug Evaluation and Research at the US Food and Drug Administration (FDA) is developing a process to qualify biomarkers for use under particular conditions. As part of this effort, Goodsaid et al. have carried out work, described in this issue, on the formal qualification of novel biomarkers of acute renal toxicity in animals. The authors' experiences highlight the importance of collaboration and the role of regulators.
Related Concept Videos
Drug Regulation
Global Regulatory Systems
Drug Control Governance: Regulatory Bodies and Their Impact
Ethics in Research
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Positive Regulator Molecules

